Have Insiders Been Buying Chembio Diagnostics, Inc. (NASDAQ:CEMI) Shares?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we’ll take a look at whether insiders have been buying or selling shares in Chembio Diagnostics, Inc. (NASDAQ:CEMI).

Do Insider Transactions Matter?

It’s quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, most countries require that the company discloses such transactions to the market.

Insider transactions are not the most important thing when it comes to long-term investing. But equally, we would consider it foolish to ignore insider transactions altogether. As Peter Lynch said, ‘insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.’

See our latest analysis for Chembio Diagnostics

The Last 12 Months Of Insider Transactions At Chembio Diagnostics

In the last twelve months, the biggest single purchase by an insider was when Director John Potthoff bought US$116k worth of shares at a price of US$5.81 per share. So it’s clear an insider wanted to buy, at around the current price. That means they have been optimistic about the company in the past, though they may have changed their mind. In any event it’s generally a positive if insiders are buying shares at around the current price.

Over the last year, we can see that insiders have bought 49.82k shares worth US$317k. In total, Chembio Diagnostics insiders bought more than they sold over the last year. They paid about US$6.37 on average. I’d consider this a positive as it suggests insiders see value at around the current price, which is US$5.98. You can see the insider transactions over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

NasdaqCM:CEMI Insider Trading December 17th 18
NasdaqCM:CEMI Insider Trading December 17th 18

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Chembio Diagnostics Insiders Bought Stock Recently

It’s good to see that Chembio Diagnostics insiders have made notable investments in the company’s shares. In total, insiders bought US$217k worth of shares in that time, and we didn’t record any sales whatsoever. This could be interpreted as suggesting a positive outlook.

Does Chembio Diagnostics Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Chembio Diagnostics insiders own 12% of the company, currently worth about US$12m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Does This Data Suggest About Chembio Diagnostics Insiders?

It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss last year, which makes us a little cautious. Insiders likely see value in Chembio Diagnostics shares, given these transactions (along with notable insider ownership of the company). Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Chembio Diagnostics.

But note: Chembio Diagnostics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.